Rehabilitative Management of Patients with Parkinson's Disease and other Neurogenerative Diseases is organized by Education Resources, Inc. (ERI) and will be held from Jul 17 - 18, 2020 at Robert Wood Johnson University Hospital - Somerset, Somerset, New Jersey, United States of America.
PTs, PTAs, OTs, and SLPs involved in the care of patients with neurodegenrative conditions, ranging from young adults to geriatric pateints.
• This course meets the criteria for 13 contact hours (1.3 CEUs). This course meets the requirements of acceptable continuing education by the NE Board of Physical Therapy. This course satisfies CE requirements in IA. In MA and NH this workshop meets accepted standards for continuing competence activities for 13 contact hours (1.3 CEUs). In CT this workshop meets accepted standards for continuing competence. Application has been made to the NJ Physical Therapy Examiners. The KS, MO, PA, and RI Boards of Physical Therapy recognize other state board's approvals.
• Approved provider by the NY State Board of Physical Therapy for 15.6 hours
• Application has been made to the FL Physical Therapy Association for 15.5 continuing education contact hours.
• Approved provider of continuing education by the American Occupational Therapy Association #3043, for 13 contact hours (1.3 CEUs) - Intermediate Level Occupational Therapy Process: assessment, intervention.
• The assignment of AOTA CEUs does not imply endorsement of specific course content, products or clinical procedures by AOTA.
• Approved provider of the FL Board of Occupational Therapy-CE Broker
• This course is offered for up to 1.3 ASHA CEUs (Intermediate level, Professional area)
• NBCOT Professional Development Provider – 13 PDUs
• 12 hours of this course qualify toward the 20 hours requirement for NDTA re-certification
Improve your clinical skills by learning evidence-based ways to treat neurodegenerative diseases including goal writing, adaptive devices, balance training, wheelchair recommendations, energy conservation techniques, fall prevention strategies, and strength and mobility training as well as how to effectively plan for the future.
How do you define success in treatment of a progressive condition? Neurodegenerative conditions such as Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington’s disease present individuals with new, often worsening, impairments as the conditions progress. While it may come off as a daunting task, rehabilitation professionals play a crucial role in addressing the ‘now’ and preparing for the ‘what if.’
Specific motor impairments, such as freezing of gait in Parkinson’s disease or spasticity in multiple sclerosis, provide unique challenges to mobility and daily activities. Not only are there physical signs we must address in therapy services, but also the non-motor impairments. Oftentimes decreased attention, difficulty multitasking, and behavioral barriers limit our ability to maintain or improve a patient’s functional status.
This course aims to improve clinician skills from diagnosis through late-stage disease management. Literature review, video case studies, and group discussions will be useful in building your skills. Improved understanding of diagnoses, pathologies, and medical management is necessary when considering the clinical decision-making process. This information leads us to define appropriate goals, apply evidence-based interventions, and care for all of the complexities that come along with an uphill battle against neurodegeneration.
At the end of the course, attendees will be able to:
• Summarize fundamentals of pathology associated with PD, secondary parkinsonisms, typicalparkinonisms, MS, ALS, and HD
• Identify clinical signs and symptoms of PD and parkinsonisms, MS, ALS, and HD
○ Describe motor and non-motor signs of PD and parkinsonisms
○ Summarize various cognitive impairments and their impact on functional mobility
• Summarize the mechanism of action, clinical candidacy, and common side effects of disease-specific medications of PD, MS, ALS, and HD
• Identify appropriate outcome measures related to disease-specific impairments of PD, MS, ALS, and HD
• Apply research-based interventions for PD, MS, ALS, and HD
• Describe long-term management of patients with PD, MS, ALS, and HD through all therapy
services and community-based programs
|Contact No. :||508-359-6533
|Registration Type||Last Date||Price|
|Course Fee||16 Jul,2020||USD 435.00|